Cerebras
CBRS
$196.13
-6.54%
Cerebras Systems Inc. is an AI company that designs and builds the world's largest semiconductor chips and AI supercomputers for training and inference, targeting the high-performance computing segment of the semiconductor industry. The company differentiates itself through its wafer-scale engine technology, which offers a unique alternative to traditional GPU-based systems, and has secured strategic partnerships with major players like OpenAI and AWS. Since its IPO in May 2026, the stock has been a focal point of investor debate, driven by its explosive revenue growth and massive backlog, but tempered by concerns over valuation, gross margin guidance, and the volatility typical of newly listed AI names. The narrative centers on whether Cerebras can translate its technological edge and customer wins into sustainable profitability and market share gains against entrenched competitors like Nvidia.…
CBRS
Cerebras
$196.13
Related headlines
Investment Opinion: Should I buy CBRS Today?
Rating: Hold. Cerebras is a high-growth, high-risk stock with a unanimous Strong Buy analyst consensus and an average price target of $291.64, implying 48.7% upside. However, the extreme valuation (131x sales) and persistent losses warrant caution. The thesis is that the company's technological leadership and massive backlog justify a premium, but the current price already reflects much of the optimism, leaving limited margin of safety.
Sign up to view all
CBRS 12-Month Price Forecast
The AI assessment is neutral, reflecting a balance between strong growth and extreme valuation. The company's technology and backlog are compelling, but the stock's price already embeds high expectations. A bullish stance would be justified if the company demonstrates sustained profitability and margin expansion, while a bearish stance would be triggered by growth deceleration or competitive losses. Key factors to monitor are quarterly revenue growth, gross margin trends, and any changes in analyst targets.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cerebras's 12-month outlook, with a consensus price target around $291.64 and implied upside of +48.7% versus the current price.
Average Target
$291.64
0 analysts
Implied Upside
+48.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$209 - $330
Analyst target range
Cerebras is covered by 11 analysts, with a consensus recommendation of 'Strong Buy' and a mean rating of 1.45 (where 1 is Strong Buy and 5 is Sell). The average price target is $291.64, implying a 48.7% upside from the current price of $196.13. The target range spans from $209.00 (low) to $330.00 (high), with the low target still 6.6% above the current price, indicating that even the most bearish analyst sees some upside. The high target suggests a 68.3% upside, reflecting optimism about the company's growth trajectory and backlog. Recent ratings from firms like Rosenblatt, UBS, and Morgan Stanley have all been positive, with no downgrades, signaling sustained institutional confidence. The wide spread between the low and high targets (58% difference) highlights the high uncertainty surrounding the stock's future, typical of a newly public, high-growth AI company.
Drowning in data?
Find the real signal!
Bulls vs Bears: CBRS Investment Factors
Cerebras presents a classic high-growth, high-risk investment. The bull case rests on explosive revenue growth (94.35% YoY), a massive $25B backlog, and improving margins, supported by a unanimous Strong Buy analyst consensus. However, the bear case is equally compelling: the stock trades at 131x sales, remains unprofitable, and has been in a sharp downtrend since its IPO. The single most important tension is whether the company can convert its technological edge and backlog into sustainable profitability and market share gains against Nvidia, or whether the extreme valuation will continue to compress as growth inevitably decelerates. Currently, the bearish evidence on valuation and price momentum slightly outweighs the bullish growth narrative, making the stock a high-risk speculative buy rather than a core holding.
Bullish
- Explosive Revenue Growth Accelerating: Q1 2026 revenue surged 94.35% YoY to $193.4M, accelerating from 72.3% growth in Q4 2025. This demonstrates strong market demand for Cerebras' wafer-scale AI chips, with the growth rate nearly doubling the industry average.
- Massive Backlog and Strategic Partnerships: The company holds a $25 billion backlog with key customers including OpenAI and AWS. These partnerships validate the technology and provide multi-year revenue visibility, supporting the strong analyst consensus.
- Improving Profitability Trajectory: Gross margin expanded to 44.56% in Q1 2026 from 40.97% in Q4 2025, while operating margin improved from -19.68% to -7.77%. Net loss narrowed dramatically to $14.0M from $105.7M in Q4 2024, indicating a clear path toward breakeven.
- Strong Analyst Conviction: All 11 analysts rate the stock a Strong Buy with a mean rating of 1.45. The average price target of $291.64 implies 48.7% upside, and even the lowest target of $209 is 6.6% above the current price.
Bearish
- Extreme Valuation with No Earnings: At 131.28x trailing sales and 153.99x forward earnings, the stock trades at a massive premium to the semiconductor industry average PS of ~10x. The trailing PE of 758.71x implies the market is pricing in years of hyper-growth with no margin for error.
- Persistent Losses and Negative FCF: Despite revenue growth, the company remains unprofitable with a net loss of $14.0M in Q1 2026 and negative free cash flow of -$119.6M. ROE is -41.1%, and the company has yet to demonstrate sustainable profitability.
- Sharp Post-IPO Downtrend: The stock has fallen 23.62% over the past three months and is down 13.72% from its 52-week high. It sits at the 16th percentile of its 52-week range, with relative strength of -26.31% versus the S&P 500, indicating persistent selling pressure.
- Gross Margin Below Industry Norms: At 44.56%, gross margin is well below the 50%+ typical of mature semiconductor companies. Management's disappointing margin guidance has been a key concern, suggesting competitive pricing pressure and higher costs.
CBRS Technical Analysis
Cerebras has been in a pronounced downtrend since its IPO, with the stock currently trading at $196.13, down 13.72% from its 52-week high of $386.34 and only 22% above its 52-week low of $160.81. The stock has lost 23.62% over the past three months, and its relative strength versus the S&P 500 over that period is -26.31%, indicating significant underperformance. The current price sits at the 16th percentile of its 52-week range, suggesting the stock is near the lower end of its trading band, which could be seen as a value opportunity or a sign of persistent selling pressure.
Beta
—
—
Max Drawdown
-45.8%
Largest decline past year
52-Week Range
$161-$386
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CBRS Return | S&P 500 |
|---|---|---|
| 1m | -6.5% | +3.6% |
| 3m | -23.6% | +2.7% |
| 6m | — | +11.4% |
| 1y | — | +18.7% |
| ytd | — | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRS Fundamental Analysis
Cerebras reported Q1 2026 revenue of $193.4 million, a 94.35% year-over-year increase, accelerating from the 72.3% growth seen in Q4 2025. The company's gross margin improved to 44.56% in Q1 2026, up from 40.97% in the prior quarter, but still below the 50%+ levels typical of mature semiconductor companies. Despite the revenue surge, the company remains unprofitable, with a net loss of $14.0 million in Q1 2026, though this loss narrowed significantly from the $105.7 million loss in Q4 2024. Operating margin was -7.77% in Q1 2026, a substantial improvement from -19.68% in Q4 2025, indicating progress toward profitability. The company's balance sheet shows a current ratio of 2.15 and a debt-to-equity ratio of -0.45, reflecting a net cash position, with $2.75 billion in cash at the end of Q1 2026. Free cash flow was negative at -$119.6 million in Q1 2026, but the company raised significant capital through its IPO, providing ample liquidity to fund operations. ROE is -41.1%, reflecting the company's losses relative to shareholder equity, but the improving operating trends suggest a path to positive returns.
Quarterly Revenue
$193406000.0B
2026-03
Revenue YoY Growth
+94.3%
YoY Comparison
Gross Margin
44.6%
Latest Quarter
Free Cash Flow
$145070500.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRS Overvalued?
Given the company's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, and at 131.28x trailing sales, it is extremely elevated. The forward PE of 153.99x, based on analyst estimates, implies the market expects significant earnings growth, but the gap between the trailing PE of 758.71x and forward PE highlights the aggressive growth assumptions embedded in the stock price. Compared to the semiconductor industry average PS ratio of approximately 10x, Cerebras trades at a massive premium, reflecting its high growth but also pricing in perfection. Historically, the stock's PS ratio has ranged from 101x to 925x since its IPO, and the current level is near the lower end of that range, suggesting the market has already de-rated the stock significantly from its peak. The EV/Sales multiple of 63.79x further underscores the rich valuation, which leaves little room for error in execution.
PE
758.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
848.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Cerebras is unprofitable, with a net loss of $14.0M in Q1 2026 and negative free cash flow of -$119.6M, though the loss narrowed from $105.7M in Q4 2024. The company's gross margin of 44.56% is below the 50%+ typical of mature semiconductor peers, and management's disappointing margin guidance suggests potential pricing pressure. With a current ratio of 2.15 and $2.75B in cash, liquidity is adequate, but the negative ROE of -41.1% indicates that shareholder equity is being eroded by losses. Revenue concentration is a concern, as a few key customers (OpenAI, AWS) account for a significant portion of the $25B backlog, and any loss of these contracts would severely impact growth.
FAQ
The key risks are: (1) Financial: persistent losses and negative FCF, with a net loss of $14M in Q1 2026; (2) Competitive: Nvidia's dominance and potential new entrants could erode market share; (3) Valuation: at 131x sales, any growth disappointment could trigger a sharp de-rating; (4) Company-specific: customer concentration with OpenAI and AWS, and execution risk on the $25B backlog. The most severe risk is a combination of growth deceleration and margin compression, which could send the stock to the 52-week low of $160.81, a -18% downside from current levels.
Based on the three scenarios, the base case (50% probability) sees the stock trading between $220 and $280, with an average target of $291.64. The bull case (25% probability) targets $280-$330, while the bear case (25% probability) could see $160-$220. The most likely scenario is the base case, assuming revenue growth continues at 80-90% and margins stabilize. The stock is currently at $196.13, so the base case implies a 12-43% upside, but the bear case highlights the risk of a further decline.
CBRS is significantly overvalued relative to its fundamentals. Trading at 131x trailing sales versus the semiconductor industry average of ~10x, the market is paying a massive premium for growth. The forward PE of 154x implies the market expects earnings to materialize quickly, but the company is still losing money. Historically, the PS ratio has ranged from 101x to 925x, and the current level is near the lower end, suggesting the stock has de-rated but remains expensive. The valuation implies the market expects near-perfect execution and sustained hyper-growth.
CBRS is a high-risk, high-reward stock. With a Strong Buy consensus and 48.7% upside to the average target, it could be a good buy for aggressive growth investors who believe in the AI infrastructure story. However, the 131x sales valuation and negative earnings mean there is little room for error. The stock is down 23.6% over three months, suggesting the market is already pricing in some risk. A good buy for those who can tolerate a potential 50% drawdown and have a 3-5 year horizon, but not for the faint-hearted.
CBRS is more suitable for long-term investment (3-5 years) given its high volatility and early-stage profitability. The stock has a beta-like volatility, with a max drawdown of -45.83% and a 1-month relative strength of -8.97%, making it risky for short-term trading. The company's growth story and backlog suggest that long-term investors who can withstand volatility may be rewarded. However, short-term traders could also profit from the wide price swings, but they face significant timing risk. A minimum holding period of 3 years is recommended to allow the company to execute on its backlog and move toward profitability.
